A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer. (Record no. 26096147)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02213 a2200613 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517100829.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201801s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1557-3265 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1158/1078-0432.CCR-15-3068 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Gaponova, Anna V |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20180131 |
| 245 00 - TITLE STATEMENT | |
| Title | A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Clinical cancer research : an official journal of the American Association for Cancer Research |
| Date of publication, distribution, etc. | Oct 2016 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 5120-5129 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Animals |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents, Phytogenic |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Apoptosis |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Camptothecin |
| General subdivision | analogs & derivatives |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Carboplatin |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cell Cycle Checkpoints |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cell Line, Tumor |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | DNA Damage |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Delivery Systems |
| General subdivision | methods |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Synergism |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | HSP90 Heat-Shock Proteins |
| General subdivision | antagonists & inhibitors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Irinotecan |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Lung Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mice |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mice, SCID |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Resorcinols |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Signal Transduction |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Small Cell Lung Carcinoma |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Xenograft Model Antitumor Assays |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Nikonova, Anna S |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Deneka, Alexander |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kopp, Meghan C |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kudinov, Alexander E |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Skobeleva, Natalia |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Khazak, Vladimir |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ogawa, Luisa S |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cai, Kathy Q |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Duncan, Kelly E |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Duncan, James S |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Egleston, Brian L |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Proia, David A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Boumber, Yanis |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Golemis, Erica A |
| 773 0# - HOST ITEM ENTRY | |
| Title | Clinical cancer research : an official journal of the American Association for Cancer Research |
| Related parts | vol. 22 |
| -- | no. 20 |
| -- | p. 5120-5129 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1158/1078-0432.CCR-15-3068">https://doi.org/10.1158/1078-0432.CCR-15-3068</a> |
| Public note | Available from publisher's website |
No items available.